View in EDS

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.

Saved in:
Bibliographic Details
Title: Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
Authors: Hecht JR; Division of Hematology/Oncology, David Geffen School of Medicine at University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA., Park YS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Tabernero J; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain., Lee MA; School of Medicine, The Catholic University of Korea, Seoul, South Korea., Lee S; Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, South Korea., Virgili AC; Medical Oncology Department, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Van den Eynde M; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Institut de Recherche Clinique et Experimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium., Fontana E; Drug Development Unit, Sarah Cannon Research Institute, London, UK., Fakih M; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Asghari G; Department of Medical Oncology, Bankstown Hospital, Bankstown, NSW, Australia., So J; Medical Oncology, Harbour Cancer and Wellness, Auckland, New Zealand., Stein A; Hematology-Oncology Practice Eppendorf, University Cancer Center, Hamburg, Germany., Dubreuil O; Medical Oncology Unit, Diaconesses-Croix St Simon Hospital, Paris, France., Bodnar L; Department of Oncology, Institute of Health Sciences, University of Siedlce, Siedlce, Poland., He CS; Exelixis, Alameda, CA, USA., Wang G; Exelixis, Alameda, CA, USA., Smith R; Exelixis, Alameda, CA, USA., Eng C; Department of Medicine, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Saeed A; Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh Medical Center and UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: saeeda3@upmc.edu.
Corporate Authors: STELLAR-303 study investigators
Source: Lancet (London, England) [Lancet] 2025 Nov 15; Vol. 406 (10517), pp. 2360-2370. Date of Electronic Publication: 2025 Oct 20.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41130252
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hecht+JR%22">Hecht JR</searchLink>; Division of Hematology/Oncology, David Geffen School of Medicine at University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Park+YS%22">Park YS</searchLink>; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Tabernero+J%22">Tabernero J</searchLink>; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Lee+MA%22">Lee MA</searchLink>; School of Medicine, The Catholic University of Korea, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Lee+S%22">Lee S</searchLink>; Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Virgili+AC%22">Virgili AC</searchLink>; Medical Oncology Department, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Van+den+Eynde+M%22">Van den Eynde M</searchLink>; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Institut de Recherche Clinique et Experimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Fontana+E%22">Fontana E</searchLink>; Drug Development Unit, Sarah Cannon Research Institute, London, UK.<br /><searchLink fieldCode="AU" term="%22Fakih+M%22">Fakih M</searchLink>; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Asghari+G%22">Asghari G</searchLink>; Department of Medical Oncology, Bankstown Hospital, Bankstown, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22So+J%22">So J</searchLink>; Medical Oncology, Harbour Cancer and Wellness, Auckland, New Zealand.<br /><searchLink fieldCode="AU" term="%22Stein+A%22">Stein A</searchLink>; Hematology-Oncology Practice Eppendorf, University Cancer Center, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Dubreuil+O%22">Dubreuil O</searchLink>; Medical Oncology Unit, Diaconesses-Croix St Simon Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Bodnar+L%22">Bodnar L</searchLink>; Department of Oncology, Institute of Health Sciences, University of Siedlce, Siedlce, Poland.<br /><searchLink fieldCode="AU" term="%22He+CS%22">He CS</searchLink>; Exelixis, Alameda, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+G%22">Wang G</searchLink>; Exelixis, Alameda, CA, USA.<br /><searchLink fieldCode="AU" term="%22Smith+R%22">Smith R</searchLink>; Exelixis, Alameda, CA, USA.<br /><searchLink fieldCode="AU" term="%22Eng+C%22">Eng C</searchLink>; Department of Medicine, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Saeed+A%22">Saeed A</searchLink>; Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh Medical Center and UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: saeeda3@upmc.edu.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22STELLAR-303+study+investigators%22">STELLAR-303 study investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2025 Nov 15; Vol. 406 (10517), pp. 2360-2370. <i>Date of Electronic Publication: </i>2025 Oct 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41130252
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(25)02025-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2360
    Titles:
      – TitleFull: Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hecht JR
      – PersonEntity:
          Name:
            NameFull: Park YS
      – PersonEntity:
          Name:
            NameFull: Tabernero J
      – PersonEntity:
          Name:
            NameFull: Lee MA
      – PersonEntity:
          Name:
            NameFull: Lee S
      – PersonEntity:
          Name:
            NameFull: Virgili AC
      – PersonEntity:
          Name:
            NameFull: Van den Eynde M
      – PersonEntity:
          Name:
            NameFull: Fontana E
      – PersonEntity:
          Name:
            NameFull: Fakih M
      – PersonEntity:
          Name:
            NameFull: Asghari G
      – PersonEntity:
          Name:
            NameFull: So J
      – PersonEntity:
          Name:
            NameFull: Stein A
      – PersonEntity:
          Name:
            NameFull: Dubreuil O
      – PersonEntity:
          Name:
            NameFull: Bodnar L
      – PersonEntity:
          Name:
            NameFull: He CS
      – PersonEntity:
          Name:
            NameFull: Wang G
      – PersonEntity:
          Name:
            NameFull: Smith R
      – PersonEntity:
          Name:
            NameFull: Eng C
      – PersonEntity:
          Name:
            NameFull: Saeed A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 11
              Text: 2025 Nov 15
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 406
            – Type: issue
              Value: 10517
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1